• Status: Closed

  • Key features: This Innovate UK and Medical Research Council programme offers funding to innovative small and medium sized businesses (SMEs) and researchers to develop solutions to healthcare challenges.

  • Programme: Other

  • Award: Varies depending on grant type

  • Opens: 05 Jun 2014, 00:00

  • Registration closes: 23 Sep 2014, 12:00

  • Closes: 01 Oct 2014, 12:00

  • Support phone number: 0300 321 4357

« go back

Biomedical Catalyst - Late stage award

Biomedical Catalyst overview - round 8

Round 8 for Early-stage and Feasibility applications will open on Thursday, 2 October 2014, with registration closing on Wednesday, 21 January 2015. The application deadline will be Wednesday, 28 January 2015.
Across the world, healthcare models are facing greater challenges, both physically and financially, in providing for a growing, ageing population with an increasing burden of disease. The long-term sustainability of current models of provision is increasingly questioned, with the upward trend in healthcare spending becoming a significant portion of a nation's GDP. The drive therefore to deliver efficient and effective healthcare has never been more pertinent.  
In order to meet these challenges, both companies and academics must recognise the drivers behind them and work together towards developing innovative technologies and processes which provide solutions for:
  • disease prevention and proactive management of health and chronic conditions
  • earlier and better detection and diagnosis of disease leading to marked improvements in patient outcomes 
  • highly effective treatments that are tailored to patients' needs and either modify the underlying disease or offer potential cures.
Supporting businesses (who are SMEs) and academics to develop solutions to these challenges, the Medical Research Council and Innovate UK are working together to deliver the Biomedical Catalyst scheme. The Biomedical Catalyst scheme will provide responsive and effective support for the best life science opportunities arising in the UK.
Support is available for projects arising from any sector or discipline that are aimed at addressing healthcare challenges. Example solutions may include (but are not limited to); stratified healthcare (both therapy and diagnostic components), regenerative medicine, diagnostics, eHealth and mHealth solutions, enabling medical technologies and devices. 
Grant funding through the Biomedical Catalyst is available to UK businesses (SMEs) and academics looking to develop innovative solutions to healthcare challenges either individually or in collaboration.
The following information relates to business-led applications only. For academic-led applications, please see the Medical Research Council website.
There are three categories of award available under the scheme, which are designed to support the evolution of an idea from concept to commercialisation. Applicants must decide which award category is most appropriate for their work. 

Late-stage award

This grant takes a well-developed concept and demonstrates its effectiveness in a relevant environment through:
  • initial human proof-of-concept studies
  • demonstration of clinical utility and effectiveness
  • demonstration of safety and efficacy (including phase I and II clinical trials)
  • development of production mechanisms
  • prototyping
  • market testing
  • intellectual property protection*.

Key features of late-stage award:

Business-led applications:
  • Duration – up to three years
  • Maximum grant – £2.4m**
  • Funding proportion – SMEs up to 60% of eligible project costs
Academic-led applications:
  • Duration – no formal limit
  • Maximum grant – no formal limit
  • Funding proportion – awarded at RCUK fEC rules
* eligible cost for business-led applications only
** for each individual entity within a project

Further information

Process for  Late Awards:

Applicants will follow a 3-stage process involving a written Expression of Interest, written Full Stage and final presentation and interview in front of a committee. Progression between stages will be by invitation only and informed by independent expert review.

Out of Scope

The Biomedical Catalyst will not support work which is deemed too early stage, for example basic research, generation of pure scientific and technological knowledge, the development of research ideas, hypotheses and experimental designs without application. It will also not support work that is considered too near or at market, for example evaluations to inform labeling, approval of pharmaceutical/device by relevant authorities, laboratory accreditation, distribution or marketing activity, post-marketing studies and post-marketing surveillance.

Making an application

The Biomedical Catalyst will operate in response mode and will in essence be ‘always open'. However, to assist the processing of applications there are key submission and assessment dates (please see the document Batch Assessment Dates).
We aim to conduct assessments on a rolling basis, three times a year approximately every four months. During the life of the scheme, we will monitor the performance of the process and investigate how we may improve upon it. It is therefore important that you check the website to ensure you have accessed the most up-to-date information before you submit your application.
An individual business may only submit one project application (where it is lead partner or the only applicant) per award category per round. If more than one application per category is submitted in a round all applications will be automatically rejected for funding without assessment.
Applicants may submit a previously rejected application a maximum of one further time. Subsequent applications for the same project will be automatically rejected.

Contact details